Compare Bristol-Myers Squibb Co (BMY) vs KraneShares CSI China Internet ETF (KWEB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs KraneShares CSI China Internet ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.81 (market cap $132.45B), while KraneShares CSI China Internet ETF trades at $27.76. The key difference: Bristol-Myers Squibb Co pays a 3.89% dividend while KraneShares CSI China Internet ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals.
| BMY | KWEB | |
|---|---|---|
Market Cap | $132.45B | — |
Sector | Health | Sector/Thematic |
52-Week High | $65.89 | $42.94 |
52-Week Low | $42.60 | $23.63 |
Enterprise Value | $166.44B | — |
Dividend Yield | 3.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.72, up 0.89% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a net income margin of 18.87% and ROE of 46.7%, though debt levels have risen. Recent news highlights a $2.3 billion manufacturing investment and merger speculation with AstraZeneca, driving investor interest.
BMY presents a mixed outlook: valuation metrics like P/E of 14.26 appear attractive, and analyst consensus targets $68.56. However, risks include patent expirations, high debt, and volatile cash flows. The stock's near-term performance hinges on merger developments and execution of growth initiatives amid competitive pressures.
KWEB, the KraneShares CSI China Internet ETF, trades at $28.66, up 0.99% on the day, with a bullish technical signal from moving averages and strong trend strength indicated by ADX. Recent news highlights institutional buying, China's export growth, and AI-driven factory rebounds, though RSI levels suggest potential overbought conditions. The ETF provides exposure to Chinese internet and AI companies, with performance influenced by economic policies and tech sector developments.
The outlook for KWEB is cautiously optimistic, driven by AI expansion and government support, but risks include U.S.-China tensions and regulatory shifts. Investors may find value in its tech concentration, yet must weigh geopolitical and market volatility. Analyst sentiment is mixed, balancing growth potential against structural risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →
